Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 269

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 269
---
 expenses for the year ended December 31, 2023, were $44.5 million, compared to $40.2 million for the year ended December 31, 2022. The $4.3 million increase was primarily driven by $4.1 million of legal costs predominantly related to the EOC arbitration and other related expenses, $0.7 million of personnel expenses related to increased headcount, incentive bonuses and share-based compensation, and $1.3 million of commercial and marketing expense, offset by a decrease of $1.8 million of consulting expenses and insurance. - 187 -

Research and Development Expenses The following table presents our research and development expenses for the periods indicated (in thousands):

|                                        |     | Year Ended   
 December 31, |   2023 |     |   |   2022 |
|:---------------------------------------|:----|:-------------|-------:|:----|:--|-------:|
| Personnel expense                      |     | $            | 22,961 |     | $ | 18,526 |
| Consultants                            |     |              |  3,657 |     |   |  4,543 |
| External clinical development          |     |              | 15,341 |     |   |  8,347 |
| Clinical drug product manufacturing    |     |              |  5,516 |     |   |    818 |
| Other expense                          |     |              |  1,454 |     |   |    428 |
| Total research and development expense |     | $            | 48,929 |     | $ | 32,662 |

Research and development expenses for the year ended December 31, 2023, were $48.9 million, compared to $32.7 million for the year ended December 31, 2022. The $16.2 million increase was primarily driven by a $7.0 million increase in clinical development expenses with $5.5 million of the $7.0 million increase related to the PRECISION1 trial, $4.5 million in expenses related to headcount, consultants, and other expenses, and $4.7 million related to clinical drug product manufacturing. Cost of Goods Sold Cost of goods sold for the year ended December 31, 2023 and 2022 was $2.8 million and $1.3 million, respectively. This increase is primarily driven by royalties incurred on product sold. Impairment of